Completed PHASE4 INTERVENTIONAL 2-arm NCT00007774

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

CSP #451 - The Clinical and Economic Impact of Olanzapine in the Treatment of Schizophrenia

Sponsor: Eli Lilly and Company

Conditions Schizoaffective Disorder Schizophrenia

Updated 6 times since 2017 Last updated: Feb 3, 2009 Started: Mar 31, 1998 Primary completion: Jun 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Schizoaffective Disorder and Schizophrenia, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 6 data snapshots since 1998. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Aug 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Aug 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company
US Department of Veterans Affairs

Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Augusta, United States , Bay Pines, United States , Bedford, United States , Cleveland, United States , Detroit, United States , Durham, United States , East Orange, United States , Indianapolis, United States , Miami, United States and 8 more locations